Related Experiment Video
Updated: Feb 11, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Targeted next-generation sequencing-based sequencing of cell-free DNA in cerebrospinal fluid uncovers cancer-specific
Alexander Köpp1, Peter Westarp2, Marta Nowak3
1Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Background:
The gold standard for the diagnosis of brain tumors comprises neurosurgical biopsies or resections for tissue acquisition. Depending on the anatomical location of the tumor, this might not always be feasible. The aim of this study was to assess whether targeted sequencing of cell-free DNA (cfDNA) could be applied in a clinical setting for the detection of cancer-specific mutations in cerebrospinal fluid (CSF) and blood using a widely available panel, investigating if this approach would facilitate brain tumor diagnosis.
Methods:
Patients with newly suspected or confirmed CNS tumors or suspected leptomeningeal metastasis were included. CSF and blood were sampled for each patient. Using next-generation sequencing (NGS), targeted sequencing was performed on cfDNA. If available, matched tissue samples were also sequenced using the same gene panel.
Results:
We investigated 58 samples from 29 patients. Sequencing was successful in 16 CSF samples (55%) and 29 blood samples (100%). On average, more tumor-specific mutations were found in CSF compared to blood. Patients in whom cfDNA sequencing in CSF was successful had tumors with a significantly shorter distance to the CSF space and were larger in size. In 2 cases, where surgeries were not considered because of high surgical risk due to the anatomical locations of the lesions, the diagnosis was aided by CSF sequencing results. One primary CNS lymphoma and 1 H3 K27M diffuse midline glioma were identified, respectively.
Conclusions:
NGS-based targeted sequencing in CSF has the potential to facilitate brain tumor diagnosis in patients presenting with new cerebral lesions.
Insights
Targeted sequencing of cell-free DNA in cerebrospinal fluid (CSF) shows promise for diagnosing brain tumors when biopsies are not feasible. This liquid biopsy approach aids in detecting cancer-specific mutations, facilitating timely diagnosis and treatment.
Area of Science:
- Neuro-oncology
- Genomics
- Molecular Diagnostics
Background:
- Neurosurgical biopsies are the standard for brain tumor diagnosis but can be limited by tumor location.
- Alternative diagnostic methods are needed for inaccessible brain tumors.
- Cell-free DNA (cfDNA) analysis offers a potential non-invasive diagnostic approach.
Purpose of the Study:
- To evaluate the clinical utility of targeted sequencing of cfDNA in cerebrospinal fluid (CSF) and blood for brain tumor detection.
- To assess if this method can identify cancer-specific mutations using a standard gene panel.
- To determine if cfDNA sequencing can aid in diagnosing brain tumors, especially when biopsies are challenging.
Main Methods:
- Patients with suspected or confirmed CNS tumors or leptomeningeal metastasis were enrolled.
- CSF and blood samples were collected for cfDNA extraction.
- Next-generation sequencing (NGS) was used for targeted sequencing of cfDNA, with matched tissue sequencing when available.
Main Results:
- Sequencing was successful in 55% of CSF samples and 100% of blood samples.
- CSF cfDNA analysis detected more tumor-specific mutations than blood analysis on average.
- Successful CSF sequencing correlated with tumors closer to the CSF space and larger tumor size.
- CSF sequencing aided diagnosis in two high-surgical-risk cases, identifying primary CNS lymphoma and H3 K27M diffuse midline glioma.
Conclusions:
- NGS-based targeted sequencing of cfDNA in CSF holds significant potential for diagnosing brain tumors.
- This approach can facilitate diagnosis in patients with new cerebral lesions, particularly when conventional biopsies are not feasible.
- CSF cfDNA sequencing represents a promising advancement in neuro-oncology diagnostics.
More Related Videos
Related Concept Videos
Next-generation Sequencing
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
Cis-regulatory Sequences
Cerebrospinal Fluid
CSF Production
CSF is produced mainly in the choroid plexus, a network of capillaries and ependymal cells located within the ventricular system of the brain....
Cancers Originate from Somatic Mutations in a Single Cell
Targeted Cancer Therapies
There are several types of targeted therapies against...
Sequences

